U.S. to Announce Prices for First Drugs Picked for Medicare Negotiations

---

Drugs Subject to Negotiations

1. Eliquis, for preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer

2. Jardiance, for diabetes and heart failure, from Boehringer Ingelheim and Eli Lilly

3. Xarelto, for preventing strokes and blood clots, from Johnson & Johnson

4. Januvia, for diabetes, from Merck

5. Farxiga, for diabetes, heart failure and chronic kidney disease, from AstraZeneca

6. Entresto, for heart failure, from Novartis

7. Enbrel, for autoimmune conditions, from Amgen

8. Imbruvica, for blood cancers, from AbbVie and Johnson & Johnson

9. Stelara, for autoimmune conditions, from Johnson & Johnson

10. Fiasp and NovoLog insulin products, for diabetes, from Novo Nordisk

---

Mr. Biden and Vice President Kamala Harris are set to speak later Thursday at an event in Maryland celebrating the Medicare announcement, a sign of the issue’s importance to Mr. Biden’s legacy and Ms. Harris’s presidential hopes. At a series of campaign events last week, Ms. Harris said that efforts to “take on Big Pharma” would be among her first priorities as president.

In his statement Thursday, Mr. Biden noted that Ms. Harris had cast the tiebreaking vote for the legislation that delivered the drug price negotiation program.